A Phase 3 interventional study of Pridopidine and Placebo in Huntington Disease, sponsored by Prilenia. Completed at 58 sites in 11 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Prilenia · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 5th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2020, is one of 14 in phase 3, and was the 101st registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 499 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Prilenia has 6 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine 45 mg BID in patients with early stage HD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
45 mg pridopidine twice daily (BID)
Drug: Pridopidine
Matching placebo
Drug: Placebo
Pridopidine hard gelatin capsule
Pridopidine-matching placebo hard gelatin capsule
Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)
The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.
Time frame: From baseline to Week 65
Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)
The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.
Time frame: From baseline to Week 65.
Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT)
The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components: Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0. Total integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better.
Time frame: From baseline to Week 65
Change From Baseline in cUHDRS Total Score - Patients Off ADMs (mITT)
The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details): Total Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better. Total cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better. This sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78
Change From Baseline in Q-Motor Finger Tapping Inter-Onset Interval (IOI) Mean - Patients Off ADMs (mITT)
Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 52, Week 65, and Week 78.
Change From Baseline in Q-Motor Pronation/Supination Inter-Tap-Interval (ITI) Mean - Patients Off ADMs (mITT)
Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 52, Week 65, and Week 78.
Change in Q-Motor Pronation/Supination Inter-Onset-Interval (IOI) Mean - Patients Off ADMs (mITT)
Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 52, Week 65, and Week 78.
Change From Baseline in the UHDRS TFC Score - Patients Off ADMs (mITT)
Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78
Change From Baseline in Stroop Word Reading (SWR) - Patients Off ADMs (mITT)
Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78
Change From Baseline in Symbol Digit Modalities Test (SDMT) - Patients Off ADMs (mITT)
Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78.
Change From Baseline in Total Motor Score (TMS) - Patients Off ADMs (mITT)
Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
Time frame: Time course from baseline to Week 26, Week 39, Week 52, Week 65, and Week 78.
| Milestone | Pridopidine | Placebo |
|---|---|---|
| Started | 250 | 249 |
| Completed | 222 | 227 |
| Not completed | 28 | 22 |
| Withdrew: Withdrawal by subject | 14 | 12 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Adverse event | 4 | 7 |
| Withdrew: Death | 4 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Not further specified | 2 | 1 |
The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) | -1.18 ± 0.119 | -0.95 ± 0.119 |
The primary efficacy endpoint for this study was the change from baseline to Week 65 in the TFC (defined as the sum of all TFC 5-items ratings \[domestic chores, activities of daily living, finances, care level, and occupation\]). The TFC is the standard and well-accepted clinical scale for staging and tracking the progression of HD using functional capacity. Scores range from 0 to 13, with 13 as the least affected and 0 as complete incapacity.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Change From Baseline to Week 65 in the UHDRS TFC Score (ITT) | -1.17 ± 0.120 | -0.94 ± 0.120 |
The composite Unified Huntington Disease Rating Scale (cUHDRS) uses 4 components: Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Higher score = worse outcome. Best score=0. Worst score= 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. Best score=100. Worst score=0. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to match numbers with symbols. Scores = correct answers in 90 sec. Higher score = better outcome. Best score=120. Worst score=0. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. Higher score = better outcome. Best score=13. Worst score=0. Total integrated cUHDRS scale range: -7.6 to 24.8. The higher, the better.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Change From Baseline to Week 65 in Composite UHDRS (cUHDRS) Total Score (mITT) | -0.99 ± 0.109 | -0.88 ± 0.108 |
The composite Unified Huntington Disease Rating Scale (cUHDRS) assesses 4 components (see secondary outcome for details): Total Motor Score (TMS) for motor features. Higher score = worse outcome. Worst = 124. Stroop Word Reading (SWR) measures attention and mental flexibility. Higher score = better outcome. Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Higher score = better outcome. Total Functional Capacity (TFC) tests the capacity to maintain daily living, finances, care level, occupation. The higher, the better. Total cUHDRS scale range: -7.6 to 24.8 (assuming 150 as the max score of SWR). The higher, the better. This sensitivity analysis was performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Week 26 | 0.15 ± 0.114 | -0.31 ± 0.108 |
| Week 39 | 0.10 ± 0.130 | -0.34 ± 0.125 |
| Week 52 | -0.07 ± 0.140 | -0.48 ± 0.135 |
| Week 65 | -0.26 ± 0.143 | -0.53 ± 0.137 |
| Week 78 | -0.40 ± 0.159 | -0.54 ± 0.158 |
Quantitative (Q)-motor is a clinical assessment of fine motor skills. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. The index finger is positioned above a force transducer and is to tap as fast as possible. The start was defined as a rise of the force by 0.05 Newton above maximal baseline level. The tap ended when it dropped to 0.05 N before the maximal baseline level was reached again. The IOI refers to the time between the onset of consecutive taps (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| milliseconds (decrease = improvement) | Pridopidine | Placebo |
|---|---|---|
| Week 26 | -14.85 ± 6.846 | 6.30 ± 6.449 |
| Week 52 | -2.37 ± 7.135 | 11.95 ± 6.792 |
| Week 65 | -0.79 ± 7.365 | 23.93 ± 7.028 |
| Week 78 | 1.46 ± 7.444 | 24.36 ± 7.230 |
Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assesses the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is ITI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| milliseconds | Pridopidine | Placebo |
|---|---|---|
| Week 26 | -17.63 ± 8.029 | 20.43 ± 7.448 |
| Week 52 | -0.15 ± 9.124 | 20.07 ± 8.555 |
| Week 65 | 4.64 ± 8.380 | 28.55 ± 7.867 |
| Week 78 | 12.73 ± 9.740 | 34.97 ± 9.412 |
Quantitative (Q)-motor is a clinical assessment of fine motor skills that are crucial for daily activities. It is based on the application of pre-calibrated and temperature-controlled force transducers and 3-dimensional position sensors. Pronation/Supination assess the regularity of hand taps. The force and duration of the hand taps were recorded similarly to the speeded tapping task. One pronation/supination hand tapping measure is IOI (the faster, the better). In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| milliseconds | Pridopidine | Placebo |
|---|---|---|
| Week 26 | -16.70 ± 9.399 | 13.68 ± 8.829 |
| Week 52 | 7.40 ± 10.978 | 24.23 ± 10.467 |
| Week 65 | 7.34 ± 10.730 | 30.13 ± 10.232 |
| Week 78 | 19.21 ± 12.702 | 41.93 ± 12.435 |
Total Functional Capacity (TFC) tests the capacity to maintain domestic chores, activities of daily living, finances, care level, and occupation. Scores from 0 - 13. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Week 26 | -0.01 ± 0.131 | -0.23 ± 0.124 |
| Week 39 | -0.11 ± 0.137 | -0.31 ± 0.131 |
| Week 52 | -0.19 ± 0.149 | -0.45 ± 0.143 |
| Week 65 | -0.49 ± 0.156 | -0.54 ± 0.150 |
| Week 78 | -0.42 ± 0.166 | -0.54 ± 0.163 |
Stroop Word Reading (SWR) measures attention and mental flexibility. Pat. reads names of colors printed in black ink. Scores reflect correct responses in 45 sec. Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Week 26 | 2.34 ± 0.964 | -0.82 ± 0.916 |
| Week 39 | 2.85 ± 1.100 | -0.04 ± 1.051 |
| Week 52 | 2.73 ± 1.078 | -0.32 ± 1.039 |
| Week 65 | 1.39 ± 1.243 | -0.94 ± 1.193 |
| Week 78 | 0.91 ± 1.261 | -1.08 ± 1.249 |
Symbol Digit Modalities Test (SDMT) tests psychomotor speed and working memory. Participant has 90 sec to write match numbers with symbols. Scoring sums correct substitutions in 90 second interval (max = 110). Higher score = better outcome. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Week 26 | 0.54 ± 0.521 | -0.47 ± 0.484 |
| Week 39 | 0.82 ± 0.512 | -0.06 ± 0.478 |
| Week 52 | -0.42 ± 0.578 | -0.33 ± 0.543 |
| Week 65 | 0.35 ± 0.616 | 0.07 ± 0.576 |
| Week 78 | 0.07 ± 0.617 | -0.36 ± 0.598 |
Total Motor Score (TMS) assesses motor features (oculomotor, dysarthria, chorea, dystonia, gait, postural stability). Each rated 0 (normal) - 4 (abnormal). Higher score = worse outcome. Worst = 124. In addition to the main efficacy analyses, sensitivity analyses were performed in a sub-group of patients who were off neuroleptics AND off vesicular monoamine transporter-2 (VMAT2) inhibitors (together called antidopaminergics, or ADMs) at any time during the study.
| score on a scale | Pridopidine | Placebo |
|---|---|---|
| Week 26 | -0.21 ± 0.568 | -0.03 ± 0.530 |
| Week 39 | 0.06 ± 0.780 | 0.96 ± 0.729 |
| Week 52 | 0.47 ± 0.766 | 0.80 ± 0.720 |
| Week 65 | 0.92 ± 0.847 | 1.28 ± 0.790 |
| Week 78 | 2.19 ± 0.954 | 1.63 ± 0.916 |
Collected over From Screening until 2 weeks after End of Study/End of Treatment visit (total treatment period of up to 78 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pridopidine | 4/250 (1.6%) | 34/250 (13.6%) | 204/250 (81.6%) |
| Placebo | 1/249 (0.4%) | 21/249 (8.4%) | 212/249 (85.1%) |
| Event | Pridopidine | Placebo |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/250 | 3/249 |
| Suicide attemptPsychiatric disorders | 3/250 | 0/249 |
| Suicidal ideationPsychiatric disorders | 2/250 | 2/249 |
| AnxietyPsychiatric disorders | 1/250 | 2/249 |
| FallInjury, poisoning and procedural complications | 0/250 | 2/249 |
| SyncopeNervous system disorders | 0/250 | 2/249 |
| COVID-19 pneumoniaInfections and infestations | 2/250 | 0/249 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/250 | 0/249 |
| DelusionPsychiatric disorders | 1/250 | 1/249 |
| ParanoiaPsychiatric disorders | 1/250 | 1/249 |
| Event | Pridopidine | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 59/250 | 57/249 |
| FallInjury, poisoning and procedural complications | 55/250 | 57/249 |
| DepressionPsychiatric disorders | 26/250 | 12/249 |
| HeadacheNervous system disorders | 16/250 | 25/249 |
| DiarrheaGastrointestinal disorders | 21/250 | 22/249 |
| AnxietyPsychiatric disorders | 19/250 | 16/249 |
| NasopharyngitisInfections and infestations | 19/250 | 18/249 |
| Urinary tract infectionInfections and infestations | 11/250 | 17/249 |
| ContusionInjury, poisoning and procedural complications | 12/250 | 14/249 |
| Back painMusculoskeletal and connective tissue disorders | 12/250 | 14/249 |
| Age, Categorical(Participants) | Pridopidine | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 207 | 213 | 420 |
| >=65 years | 43 | 36 | 79 |
| Age, Continuous(years) | Pridopidine | Placebo | Total |
|---|---|---|---|
| Mean | 52.2 ± 11.93 | 52.7 ± 11.39 | 52.5 ± 11.66 |
| Sex: Female, Male(Participants) | Pridopidine | Placebo | Total |
|---|---|---|---|
| Female | 132 | 127 | 259 |
| Male | 118 | 122 | 240 |
| Race (NIH/OMB)(Participants) | Pridopidine | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 2 | 2 |
| White | 242 | 235 | 477 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 5 | 9 | 14 |
| Region of Enrollment(participants) | Pridopidine | Placebo | Total |
|---|---|---|---|
| Canada | 9 | 17 | 26 |
| Austria | 5 | 6 | 11 |
| Netherlands | 14 | 8 | 22 |
| United States | 108 | 93 | 201 |
| Czechia | 6 | 8 | 14 |
| Poland | 16 | 15 | 31 |
| Italy | 28 | 30 | 58 |
| United Kingdom | 5 | 13 | 18 |
| France | 4 | 7 | 11 |
| Germany | 37 | 41 | 78 |
| Spain | 18 | 11 | 29 |
| HD stage at randomization(Participants) | Pridopidine | Placebo | Total |
|---|---|---|---|
| HD1 | 102 | 103 | 205 |
| HD2 | 148 | 146 | 294 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Mar 2023, 28 months.
Results were first posted in Mar 2025, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Prilenia